Ashling Wahner

Evan Y. Yu, MD, discusses the clinical evolution of radiopharmaceuticals for patients with mCRPC and how PSMA PET may evolve to monitor treatment response.

Douglas Flora, MD, FACCC, LSSBB, discusses the growing role of artificial intelligence tools in oncology practice.

Nerea Lopetegui-Lia, MD, discusses fertility preservation options for patients with TNBC and considerations for managing treatment-related toxicities.

Frontline T-DXd plus pertuzumab led to statistically significant and clinically meaningful PFS improvements vs THP in HER2+ metastatic breast cancer.

R. Lor Randall, MD, FACS, discusses the importance of orthopedic oncology consensus meetings and the need for agreement about certain surgical practices.

Nerea Lopetegui-Lia, MD, discusses ongoing trials investigating ADCs that are shaking up the metastatic triple-negative breast cancer setting.

Evan Y. Yu, MD, discusses future directions for biomarker research and targeted therapy development for patients with castration-resistant prostate cancer.

Evan Y. Yu, MD, discusses PARP inhibitor treatment selection and sequencing for patients with metastatic castration-resistant prostate cancer.

A new drug application for zurletrectinib has been accepted in China for the treatment of patients with NTRK gene fusion–positive advanced solid tumors.

Nerea Lopetegui-Lia, MD, discusses the prevalence of and risk factors for triple-negative breast cancer, and strategies that may improve survival outcomes.

Treatment with the IR2 regimen led to durable responses that were favorable compared with those in chemotherapy-treated relapsed/refractory MCL.

Enhanced dermatologic management lowered rates of dermatologic AEs during first-line amivantamab/lazertinib treatment for EGFR-mutated advanced NSCLC.

Pamela T. Soliman, MD, MPH, discusses a phase 1 investigation of temsirolimus plus metformin in patients with recurrent endometrial cancer.

Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.

The FDA has awarded full approval to frontline nivolumab plus ipilimumab for the treatment of adult patients with unresectable hepatocellular carcinoma.

Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.

An independent DSMB found MaaT033 to have a favorable safety profile in patients with hematologic malignancies undergoing allo-HSCT in the PHOEBUS trial.

Chandler Park, MD, FACP, discusses optimal clinical scenarios for the use of the 3 approved first-line treatment options for patients with bladder cancer.

The FDA has granted approval to nivolumab plus ipilimumab for the treatment of patients with dMMR/MSI-H metastatic colorectal cancer.

Induction R-DA-EDOCH/R-DHAP therapy yields high rates of CR, overall response, and MRD negativity in young patients with newly diagnosed, high-risk MCL.

The combination of VXM01 and avelumab was well tolerated and has the potential to generate clinically meaningful responses in recurrent glioblastoma.

Tanios S. Bekaii-Saab, MD, discusses questions that have arisen regarding the use of immunotherapy in patients with MSI-H/dMMR and MSS/pMMR CRC.

Updated interim phase 2 data showed the clinical efficacy and safety of neoadjuvant darovasertib monotherapy in localized uveal melanoma.

Infections occur early after CAR T-cell therapy administration in patients with relapsed/refractory NHL.

Read a recap of the episodes of OncLive On Air that aired in March 2025.

D-VRd with daratumumab/lenalidomide maintenance led to sustained PFS and MRD negativity across high-risk subgroups of newly diagnosed multiple myeloma.

A comparative analysis showed that apraglutide plus ruxolitinib improved response rates vs ruxolitinib monotherapy in steroid-refractory GI aGVHD.

Nataliya Uboha, MD, PhD, discusses the benefits of expanding the first-line ESCC treatment paradigm with tislelizumab plus chemotherapy.

Steven Devine, MD; Everett Meyer, MD, PhD; and Sophie Paczesny, MD, PhD, discuss their most highly anticipated presentations from the 2025 EBMT Meeting.

The investigational new drug application for the RDC SKB107 for the management of solid tumor bone metastases has been approved in China.